Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
Abstract Maintaining consistent levodopa benefits while simultaneously controlling dyskinesia can be difficult. Recently, an amantadine delayed release/extended release (DR/ER) formulation (Gocovri®) indicated for dyskinesia received additional FDA approval as an adjunct to levodopa for the treatmen...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Portfolio
2022-03-01
|
| סדרה: | npj Parkinson's Disease |
| גישה מקוונת: | https://doi.org/10.1038/s41531-022-00291-1 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|